申请人:GLAXO GROUP LIMITED
公开号:EP0320205A2
公开(公告)日:1989-06-14
There are described new compounds of formula (1)
wherein
R¹ represents an acyl group;
X¹ represents phenylalanine or p-methoxyphenylalanine bonded N-terminally to R¹ and C-terminally to X²;
X² represents histidine or N-methylhistidine bonded N-terminally to X¹ and C-terminally to the group -NH-;
R² represents a C₄₋₆ cycloalkyl group;
R³ represents a group CHR⁶R⁷ (where R⁶ is a hydrogen atom and R⁷ is a phenyl group, or R⁶ is a methyl group and R⁷ is a hydrogen atom or a methyl or ethyl group;
X³ represents a C₂₋₆ alkylene chain optionally substituted by one or more C₁₋₄ alkyl groups;
R⁴ and R⁵, which may be the same or different, each independently represent a hydrogen atom or a C₁₋₄ alkyl group, or NR⁴R⁵ may form a 5- or 6- membered polymethylenimine ring;
and salts and solvates thereof.
The new compounds have been found to exhibit activity as renin inhinitors, combining good duration of action with significant oral potency.
Compositions containing the compounds of formula (1) and processes for preparing the compounds are also described.
所述新化合物为式(1)
其中
R¹ 代表酰基
X¹ 代表苯丙氨酸或对甲氧基苯丙氨酸,N-端与 R¹ 键合,C-端与 X² 键合;
X² 代表组氨酸或 N-甲基组氨酸,其 N 端与 X¹ 键合,C 端与基团 -NH- 键合;
R² 代表 C₄₋₆环烷基;
R³ 代表基团 CHR⁶R⁷(其中 R⁶ 是氢原子,R⁷ 是苯基,或 R⁶ 是甲基,R⁷ 是氢原子或甲基或乙基);
X³ 代表任选被一个或多个 C₁₋₄ 烷基取代的 C₂₋₆ 亚烷基链;
R⁴和R⁵可以相同或不同,各自独立地代表一个氢原子或一个C₁₋₄烷基,或者NR⁴R⁵可以形成一个5-或6-成员的聚亚甲基亚胺环;
及其盐和溶剂。
研究发现,这些新化合物具有肾素抑制剂的活性,同时具有良好的作用持续时间和显著的口服效力。
此外,还描述了含有式(1)化合物的组合物以及制备这些化合物的工艺。